Abstract
The problem of tumor cell drug resistance remains a barrier to the successful treatment of many neoplastic diseases. Problems of tumor cell heterogeneity and expression of multiple mechanisms of drug resistance complicate treatment strategies. Indeed, even that form of resistance to natural product anticancer agents, multidrug resistance (MDR), can have multiple mechanisms. Compounding these problems is the use of different methodologies and different reagents to assess expression of the most widely studied form of MDR, that due to increased expression of the MDR1 gene and its product, P-glycoprotein (Pgp). In this paper, we discuss problems associated with assay variability and accurate measurement of markers of drug resistance, and summarize consensus findings of the St Jude Workshop on methods to detect Pgp in tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beck, W., Grogan, T. Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins. Leukemia 11, 1107–1109 (1997). https://doi.org/10.1038/sj.leu.2400675
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2400675
Keywords
This article is cited by
-
Targeting multidrug resistance in cancer
Nature Reviews Drug Discovery (2006)
-
Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response
Pediatric Nephrology (2006)
-
Diagnostics of multidrug resistance in cancer
Pathology & Oncology Research (1998)